Effectiveness of Sinopharm’s BBIBP-CorV Booster Vaccination Against COVID-19-Related Severe and Critical Cases and death in Morocco During the Omicron Wave

Abstract

ObjectiveThis study investigates the effectiveness of booster doses on the Omicron wave in Morocco against COVID-19 severe and critical hospitalizations and deaths;Participants/methodsThis study uses nationally representative data on COVID-19 from 15 December 2021 to 31 January 2022. To investigate the effectiveness of the inactivated COVID-19 vaccine BBIBP-CorV (Vero Cells) Sinopharm booster doses on the Omicron wave in morocco by using real-world data established from nationally representative statistics on COVID-19 cases, deaths and vaccinations.Statistical AnalysesThe screening method was used to estimate vaccine effectiveness against COVID-19 severe or critical hospitalization and COVID-19-related deaths. The data were grouped by, age subgroup, sex, week, and geographical area and were analyzed by using binary logistic regression with an offset for vaccine coverage.ResultsThe overall sinopharm VE estimate is 89% (95% CI 85 to 92) effective in curbing COVID-19 death, and 81% (95% CI 78 to 84 in curbing COVID-19 severe critical hospitalization. Death-related VE estimate was 86% (95% CI 81 to 90) for patients aged 1Z65 years, 96% (95% CI 90 to 98) for those aged < 65 years, 95% (95% CI 88 to 98) in no risk factor patient was, 91% (95% CI 85 to 94) with 1 risk factor; 90% (95% CI 83 to 95) with 2 risk factors; 72% (95% CI 52 to 84) in patient with 3 risk factors and more. Severe critical hospitalization VE, estimate was 78% (95% CI 74 to 82) for patients aged 1Z65 years, 87% (95% CI 82 to 90) for those aged < 65 years, 86% (95% CI 80 to 90) in no risk factor patient was, 80% (95% CI 73 to 84) with 1 risk factor; 80% (95% CI 70 to 85) with 2 risk factors; 80% (95% CI 68 to 86) in patient with 3 risk factors and more.ConclusionsSinopharm Boosters are effective in increasing protection against Omicron variant-related COVID-19 death and severe critical hospitalization. The protection is reduced with older age and higher risk factors. These findings emphasize the importance of targeted vaccination strategies for different demographic groups and underscore the protective benefits of the third booster Sinopharm vaccine.